FDA Accepts Axsome Therapeutics NDA for AXS-12 in Narcolepsy Treatment

Key Facts

In a move that strengthens the company's position in the central nervous system treatment sector, Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has officially accepted its New Drug Application (NDA) for AXS-12. This innovative drug is designed to treat cataplexy in patients with narcolepsy, a chronic neurological disorder. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027, to reach a final decision on the drug's approval.

This regulatory milestone comes amid intense competition in the rare disease biotech space, as Axsome seeks to expand its portfolio following previous successes in depression treatments. In comparison to peers, Jazz Pharmaceuticals, a leader in the narcolepsy market, reported Xywav revenues of $332 million in its most recent quarter per its earnings report, highlighting the significant market opportunity for AXS-12 if approved.

Regarding market performance, AXSM stock stood at $228.28 (at close July 13, 2026), with investors monitoring for interim clinical or regulatory updates ahead of the 2027 deadline. Looking at the economic calendar, the market is awaiting the release of the FOMC Minutes later today, which could impact sentiment across the biotech and growth sectors depending on interest rate outlooks.